Which radioactive drug hits tumors harder? small study aims to find out

NCT ID NCT06516510

Terminated Knowledge-focused Sponsor: Blue Earth Therapeutics Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study compared two radioactive drugs, lutetium rhPSMA-10.1 and Pluvicto, in 17 men with metastatic prostate cancer that cannot be cured. The goal was to see which drug delivers more radiation to tumors and less to healthy organs like the kidneys. The study was terminated early, so findings are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: lutetium (177Lu) rhPSMA-10.1 and lutetium (177Lu) vipivotide tetraxetan (Pluvicto)
What this could lead to: If successful, this could help identify which drug is better at targeting tumors while sparing healthy organs, potentially improving future treatment choices.
What could go wrong: This was a very early, small study (17 people) that was terminated, so results are limited and may not apply to all patients. No treatment benefit was directly tested.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC PROSTATE CANCER

Contacts and locations

Locations

Biogenix Molecular LLC

Miami, Florida, 33165, United States
Centro Integral Oncologico Clara Campal

Madrid, Madrid, 28050, Spain
Clinica Universidad de Navarra

Madrid, 28027, Spain
Clinica Universidad de Navarra - Pamplona

Pamplona, Navarre, 31008, Spain
Emory University Hospital

Atlanta, Georgia, 30322, United States
Radboud UMC

Nijmegen, Gelderland, 6525GA, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.